focus -WSS

focus

author：entertainment 2025-10-02 06:54:06 Page View：2483

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Inequities make cancer less preventable for women: report
Next article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Shingles, which affected Dianne Feinstein, is on the rise

PicturesofSenatorDianneFeinsteinrestbyacondolencebookatCityHallinSanFranciscoonFriday.BenjaminFanjoy

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

The unintended consequences of overturning Roe v. Wade

AwomanwaitstogetamedicalabortionataPlannedParenthoodclinicinKansasCity,Kan.CharlieRiedel/APEverydaya

focus

comprehensive

explore

The unintended consequences of overturning Roe v. Wade